The Full Picture of Ulcerative Colitis: The Burden, the Patient, the Treatment - European Medical Journal

The Full Picture of Ulcerative Colitis: The Burden, the Patient, the Treatment

Download PDF
Julián Panés1,2
Edouard Louis,3 Paul Rutgeerts4

Julián Panés has received grants/research support from Abbott Laboratories and Merck Sharp & Dohme Corp.; consulting/speaker fees from AbbVie, Abbott Laboratories, Boehringer Ingelheim, Ferring, Galapagos, Genentech, Janssen Biologics, Merck Sharp & Dohme Corp., Millennium (Takeda), MSD, Pfizer, Roche, Shire, Schering-Plough, Takeda, Tigenix, and TxCell. Edouard Louis has received educational grants from MSD and Abbvie; speaker fees from Abbvie, Ferring, MSD, Chiesi, Mitsubishi Pharma, Hospira, and Janssen; and has served on advisory boards for Abbvie, Ferring, MSD, Takeda, Mitsubishi Pharma, and Celltrion.


Writing assistance was provided by Dr Allan Johnson, Medical Writing Limited.


The symposium was jointly organised and funded by Abbvie. All authors received honoraria for preparation and delivery of their presentations. The publication of this article was funded by Abbvie. This article is an interpretation of the views of the speakers, but is not written by them. The views and opinions expressed are those of the authors and not necessarily those of Abbvie.

EMJ Gastroenterol. ;4[1]:58-64. DOI/10.33590/emjgastroenterol/10314197.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Meeting Summary

Ulcerative colitis (UC) carries a significant, progressive disease burden that is often underestimated or misinterpreted by healthcare providers. Adverse outcomes have a major impact on patient quality of life, with a significant burden of symptoms both during and between inflammation flares. Chronic, uncontrolled disease leads to epithelial fibrosis and ‘lead pipe’ colon, dysplasia, and potential colonic cancer. Healthcare providers and patients share similar treatment goals, even if these are not verbalised in the same way, and clinicians need to fully understand the issues most important to patients. Understanding and collaboration can improve identification of meaningful treatment goals and overall disease management. In real-world practice, patients should be categorised according to disease characteristics and prognosis, and managed with appropriate, optimised therapies. Early, top-down management should be implemented in high-risk patients and all patient-centric therapeutic decisions made within the context of a full benefit/risk assessment.

Please view the full content in the pdf above.

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally